Lundbeck appoints new EVP, People & Communication
Valby, Denmark, 14 August 2019 - H. Lundbeck A/S (Lundbeck) today announced the appointment of Elise Hauge to the role of EVP, People & Communication. Elise will join Lundbeck on 1 September 2019 and will be part of Executive Management.
Elise will be responsible for driving Lundbeck’s people strategy across its global organization, overseeing the attraction, retention and development of best talent in the industry to ensure we retain our competitive advantage both now and into the future as our industry and company embrace new approaches and technologies.
As a leader in the field of developing strong and agile workforces, Elise brings close to 20 years of global and strategic people development experience from multiple companies and industries. Within life sciences Elise has gained diverse experiences as head of HR, Emerging Markets at Takeda and from Nycomed in Switzerland in senior HR roles and as HR transitions management responsible in the integration of Nycomed and Takeda. Before that, Elise has extensive HR experience from the financial sector at Nordea, and the IT industry with experience from both Microsoft and SimCorp. Elise holds a master’s degree in law and will join Lundbeck from a position as SVP, Chief Human Resources Officer for SimCorp A/S where she has been employed since January 2014.
“I am delighted to add to the strong executive team at Lundbeck a leader with Elise’s diverse experience and expertise to spearhead our global people strategy. In line with Lundbeck’s Expand and Invest to Grow strategy, we will continually strengthen our capabilities, making sure we are agile and well prepared for the growth and change within our industry over the years ahead,” says Deborah Dunsire, President and CEO of Lundbeck and continues: “Elise’s leadership will be important in making sure we develop and deploy our talented people in the best way possible. Lundbeck’s strength and competitive edge lie in people and we strive to continuously build a culture where the best and brightest talents can thrive and drive Lundbeck successfully into the future.”
“I am delighted that Lundbeck has offered me this great opportunity and am excited to be returning to the global pharmaceutical industry in a key executive role. Lundbeck is for sure a people business, and I am looking very much forward to help drive the people agenda forward, both with regards to attracting and retaining great talent from all over the world to Lundbeck,” says Elise Hauge.
Following today’s announcement, the executive management of Lundbeck is comprised of:
- Deborah Dunsire, President & CEO
- Peter Anastasiou, EVP, North America
- Lars Bang, EVP, Product Development & Supply
- Anders Götzsche, EVP & CFO
- Elise Hauge, EVP, People & Communication (from 1 September)
- Keld Flintholm Jørgensen, EVP & CBO
- Johan Luthman, EVP, R&D
- Jacob Tolstrup, EVP, Commercial Operations
Palle Holm Olesen Mads Kronborg
Vice President, Investor Relations Senior Director, Corporate Communication
+45 30 83 24 26 +45 36 43 40 00
About H. Lundbeck A/S
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.
An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.
Read more at www.lundbeck.com/global/about-us/progress-in-mind.
Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several R&D programs and our products are available in more than 100 countries. We have research centres in Denmark and California and our production facilities are located in Denmark, France and Italy. Lundbeck generated revenue of DKK 18,1 billion in 2018 (EUR 2,4 billion; USD 2,8 billion).
Safe Harbor/Forward-Looking Statements
The above information contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.
Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.
Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made considering past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.